The Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.
Congenital Heart Disease (CHD) is a term used to describe a range of structural defects in the heart that are present at birth. These defects can involve the walls, valves, arteries, or veins of the heart, causing problems with blood flow and affecting the heart’s ability to pump blood effectively. Some congenital heart defects are mild and may not require treatment, while others can be more severe and require medical interventions such as surgery or medication. The exact cause of most congenital heart defects is not known, but a combination of genetic and environmental factors is thought to play a role.
The growth of the global Congenital Heart Disease (CHD) market is mainly driven by rising prevalence of congenital heart disease globally. Moreover, increased awareness, improved diagnostic techniques, increased awareness and better access to healthcare are expected to drive the market further. In addition, the growing emphasis on paediatric cardiology and specialized care for children are expected to drive the market further during the forecast period.
On the other hand, the high cost of treatment, limited healthcare infrastructure, and a complex regulatory environment might hamper the growth of the market during the forecast period.
The COVID-19 pandemic has had a significant impact on the growth if the Congenital Heart Disease (CHD) Market. The pandemic led to a decrease in the number of elective CHD surgeries, as hospitals prioritized the treatment of COVID-19 patients. Moreover, there was a delay in the diagnosis and treatment of CHD, as patients have been reluctant to seek medical care due to hear of contracting COVID-19. In addition, the pandemic led to an increase in the risk of complications for patients with CHD who do not contract COVID-19.
The Congenital Heart Disease (CHD) market is expected to grow during the forecast period. This growth can be attributed to several factors. Firstly, the prevalence of CHD is estimated to be between 8 to 12 per 1000 live births. This means that about 1 in 100 new borns will have some form of CHD. Moreover, the survival rates for children with CHD have improved significantly in recent years. This is due to advances in medical technology, such as minimally invasive surgery and heart transplantation. In addition, there is a growing awareness of CHD among the general public and healthcare professionals. This is leading to earlier diagnosis and treatment of CHD, which is improving outcomes for patients.
North America to Dominate the Market